---
title: "Inovio Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286618174.md"
description: "Inovio Pharmaceuticals Inc. (INO) shares fell 4.41% to $1.30 on Friday, underperforming against competitors like Johnson & Johnson and Pfizer. The NASDAQ Composite Index dropped 1.54%, while Inovio's stock remains 56.36% below its 52-week high of $2.98. Trading volume was 1.9 million, below the 50-day average of 2.7 million."
datetime: "2026-05-15T21:24:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286618174.md)
  - [en](https://longbridge.com/en/news/286618174.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286618174.md)
---

# Inovio Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Inovio Pharmaceuticals Inc. (INO) shed 4.41% to $1.30 Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index falling 1.54% to 26,225.14 and Dow Jones Industrial Average falling 1.07% to 49,526.17.

Inovio Pharmaceuticals Inc. closed 56.36% short of its 52-week high of $2.98, which the company reached on September 9th.

The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) fell 1.77% to $226.71, Statera Biopharma Inc. (STAB) remained unchanged, and Pfizer Inc. (PFE) fell 1.63% to $25.33.

Trading volume (1.9 M) remained 715,728 below its 50-day average volume of 2.7 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 15, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-15-26 1724ET

### Related Stocks

- [INO.US](https://longbridge.com/en/quote/INO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [Artiva says AB-101 plus rituximab posts 71% ACR50 response in refractory RA study](https://longbridge.com/en/news/286959967.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)